Table 6.
Characteristic % (n) | High Complexity | |||||
---|---|---|---|---|---|---|
MRCI ≥25.1 | MRCI ≥23.8 | MRCI ≥21.0 | MRCI ≥17.0 | MRCI ≥16.5 | MRCI ≥15.5 | |
Number of patients | 4 | 7 | 15 | 26 | 30 | 39 |
Female | 50 (2) | 57.1(4) | 60.0 (9) | 53.8 (14) | 56.7 (17) | 61.5 (24) |
Studied for up to 8 years | 50 (2) | 57.2 (4) | 66.6 (10) | 65.3 (17) | 66.7 (20) | 66.7 (26) |
Number of clinical conditions1 | 4.5 (3.3;5.8) | 5.0 (3.0;6.0) | 4.0 (3.0;5.0) | 4.0 (2.8;5.0) | 3.5 (2.0;5.0) | 4.0 (2.0;4.0) |
Cardiovascular disease1 | 1.0 (1.0;1.8) | 1.5 (1.0;2.3) | 1.0 (1.0;2.0) | 1.0 (1.0;1.5) | 1.0 (1.0;1.0) | 1.0 (1.0;1.0) |
Endocrine/metabolic disease1 | 2.5 (1.3;3.0) | 2.0 (1.0;3.0) | 1.0 (1.0;2.0) | 2.0 (1.0;2.0) | 2.0 (1.0;2.0) | 2.0 (1.0;2.0) |
Number of medical appointments per year1 | 4.0 (3.0;6.0) | 4.0 (3.0;7.5) | 3.0 (2.0;4.8) | 4.0 (2.0;9.0) | 4.0 (2.0;8.0) | 3.5 (2.7;8.0) |
Number of drugs1 | 9.0 (8.3;9.8) | 9.0 (7.0;9.0) | 7.0 (6.0;9.0) | 7.0 (6.0;7.3) | 7.0 (5.0;7.0) | 6.0 (5.0;7.0) |
Polypharmacy | 100 (4) | 100 (7) | 100 (15) | 92.3 (24) | 93.3 (28) | 94.9 (37) |
All medicines were accessed by PHS | 50 (2) | 71.4 (5) | 66.7 (10) | 80.8 (21) | 80.0 (24) | 82.1(32) |
Has at least one PDRP | 100 (4) | 100 (7) | 93.3 (14) | 88.5 (23) | 86.7 (26) | 87.2 (34) |
Adherence | 100 (4) | 100 (7) | 80.0 (12) | 80.8 (21) | 83.3 (25) | 84.6 (33) |
Median (Percentile 25; Percentile 75)